Holen Sie sich die Stockscreener-App
0.0692
26.38%
-0.0248
Handel nachbörslich:
.07
0.0008
+1.16%
Schlusskurs vom Vortag:
$0.094
Offen:
$0.083
24-Stunden-Volumen:
9.39M
Relative Volume:
1.95
Marktkapitalisierung:
$3.79M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-26.38%
1M Leistung:
-30.80%
6M Leistung:
-92.31%
1J Leistung:
+0.00%
1-Tages-Spanne:
$0.068
$0.0836
1-Wochen-Bereich:
$0.068
$0.107
52-Wochen-Spanne:
$0.068
$4.31
Psyence Biomedical Ltd Stock (PBM) Company Profile
Firmenname
Psyence Biomedical Ltd
Sektor
Branche
Telefon
-
Adresse
-
Psyence Biomedical Ltd Aktie (PBM) Neueste Nachrichten
Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs - Yahoo Finance
Psyence Biomedical Announces Closing of Previously Announced Acquisition of Psyence Group's Stake in PsyLabs - The Manila Times
Psyence Biomedical Announces Closing of Previously Announced Acquisition of Psyence Group’s Stake in PsyLabs - StockTitan
Where Do Analysts See Psyence Biomedical Ltd. (NASDAQ: PBM) Heading? - Stocks Register
Bullish Prospects For Psyence Biomedical Ltd. (NASDAQ: PBM) Shares In 2024 - Stocks Register
Psyence Biomed adds Australian site for psilocybin trial - Investing.com
Psyence Biomed adds Australian site for psilocybin trial By Investing.com - Investing.com South Africa
Psyence Biomed Announces Recruitment of Second Clinical - GlobeNewswire
Psyence Biomed Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care - StockTitan
Psyence Biomedical Sets Annual General Meeting for November 12 - Investing.com
Psyence Biomedical Plans Key Shareholder Meeting - TipRanks
Psyence Biomedical Sets Annual General Meeting for November 12 By Investing.com - Investing.com UK
Psyence Biomed Provides Progress Update on PsyLabs E.U. Good Manufacturing Practices (GMP) Certified Active Pharmaceutical Ingredient (API) Development - The Manila Times
Psyence Biomedical Ltd. (PBM) Stock: 52-Week Performance Insights and Trading Volume - The InvestChronicle
How analysts predict Psyence Biomedical Ltd. (PBM) will perform this quarter? - US Post News
Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical - The Manila Times
Gaining Ground: Psyence Biomedical Ltd. (PBM) Closes Higher at 0.10, Up 5.70 - The Dwinnex
What is Psyence Biomedical Ltd. (PBM) Stock Return on Shareholders’ Capital? - SETE News
Psyence Biomedical Ltd. [PBM] is -98.82% lower this YTD. Is it still time to buy? - The DBT News
Investor Alert: What’s Really Going On At Psyence Biomedical Ltd. (NASDAQ: PBM) - Stocks Register
There is no way Psyence Biomedical Ltd. (PBM) can keep these numbers up - SETE News
Psyence Biomedical Converts Debt to Equity - TipRanks
PBM’s Stock Journey: What Investors Need to Know About Psyence Biomedical Ltd.’s Performance - The InvestChronicle
Is it possible to buy Psyence Biomedical Ltd.(PBM) shares at a good price now? - US Post News
Financial Analysis: Psyence Biomedical Ltd. (PBM)’s Ratios Unveil Key Insights - The Dwinnex
PBMPsyence Biomedical Ltd. Common Shares Latest Stock News & Market Updates - StockTitan
Psyence Biomed halts Clairvoyant Therapeutics acquisition - Investing.com
Psyence Biomed halts Clairvoyant Therapeutics acquisition By Investing.com - Investing.com UK
Psyence Biomed Provides Update on Previously Announced Acquisition of Clairvoyant - The Manila Times
Views of Wall Street’s Leading Experts on Psyence Biomedical Ltd. - SETE News
Psyence Biomedical Ltd. (PBM) Stock: Uncovering 52-Week Market Trends - The InvestChronicle
Market Momentum: Psyence Biomedical Ltd. (PBM) Registers a -1.10 Decrease, Closing at 0.11 - The Dwinnex
Psyence Biomedical Ltd. (PBM) stock analysis: A comprehensive overview - US Post News
Psyence Biomedical Ltd. (PBM): Be Patient, You Will Learn - Stocks Register
An analyst sees good growth prospects for Psyence Biomedical Ltd. (PBM) - SETE News
A stock that deserves closer examination: Psyence Biomedical Ltd. (PBM) - US Post News
Stock Performance Spotlight: Psyence Biomedical Ltd. (PBM) Ends the Day at 0.12, Down by -6.11 - The Dwinnex
Psyence Group Sells Stake to Psyence Biomedical - TipRanks
Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs - Yahoo Finance
Psyence Biomed acquires stake in PsyLabs for $1.1 million By Investing.com - Investing.com Canada
Psyence Biomed acquires stake in PsyLabs for $1.1 million - Investing.com
Psyence Biomed Enters into Agreement to Acquire Stake in PsyLabs - StockTitan
Psyence inks several deals to expand psilocybin research, footprint - Green Market Report
A new trading data show Psyence Biomedical Ltd. (PBM) is showing positive returns. - SETE News
Psyence Biomedical Ltd. (PBM) Stock: A Year of Declines and Increases - The InvestChronicle
Balance Sheet Insights: Psyence Biomedical Ltd. (PBM)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Psyence Biomedical Trials Psilocybin for Palliative Care - TipRanks
Psyence CEO says positioned ‘to be a leader’ in psychedelic-based therapeutics - TipRanks
Psyence Biomedical Ltd. (PBM) did well last session? - US Post News
Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones - StockTitan
Psyence Biomed Issues Shareholder Update Recapping Recent - GlobeNewswire
Finanzdaten der Psyence Biomedical Ltd-Aktie (PBM)
Es liegen keine Finanzdaten für Psyence Biomedical Ltd (PBM) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.11%
0.26%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):